On May 14, BeiGene announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval to sonrotoclax (trade names: BEQALZI™) for adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) who have received at least two prior lines of systemic therapy, including a Bruton's tyrosine kinase (BTK) inhibitor.
Sonrotoclax is a next-generation BCL2 inhibitor with cornerstone potential in the BCL2 inhibitor space. Its design aims to enhance BCL2 inhibitory activity, with optimized molecular potency and selectivity. Its pharmacological profile is expected to improve efficacy, tolerability, and convenience in clinical use.
This approval marks the first new BCL2 inhibitor to enter the U.S. market in ten years, and sonrotoclax is currently the only BCL2 inhibitor approved in the United States for the MCL indication.
The accelerated approval was supported by efficacy and safety data from the Phase 1/2 study BGB-11417-201 (NCT05471843). Results were presented at the 67th American Society of Hematology (ASH) Annual Meeting. The independently reviewed efficacy data are as follows:
• Overall response rate (ORR): 52% (95% CI: 42–62)
• Complete response (CR) rate: 16% (95% CI: 9.1–24.0)
• Median time to response (TTR): 1.9 months
• Median duration of response (DOR): 15.8 months (95% CI: 7.4 months to not estimable), with a median follow-up of 11.9 months (data not yet mature)
• Safety: Sonrotoclax monotherapy was generally well tolerated.
Continued approval for this indication is contingent on the ongoing CELESTIAL-RRMCL confirmatory trial (NCT06742996) demonstrating clinical benefit. The FDA has granted sonrotoclax Breakthrough Therapy Designation (BTD) for this indication, as well as Fast Track Designation and Orphan Drug Designation.
Sonrotoclax has also been approved in China for R/R MCL and for adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have received at least one prior systemic therapy including a BTK inhibitor. The European Medicines Agency (EMA) and other regulatory agencies are currently reviewing Phase 1/2 study data for sonrotoclax in R/R MCL.
The FDA has additionally granted sonrotoclax Fast Track Designation for Waldenström's macroglobulinemia (WM), as well as Orphan Drug Designation for WM, multiple myeloma, acute myeloid leukemia, and myelodysplastic syndromes.
BeiGene is also exploring the combination potential of sonrotoclax with other agents, including zanubrutinib, for the treatment of CLL. Updated data from these studies are expected to be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
MCL is a rare and typically aggressive subtype of non-Hodgkin lymphoma. Approximately 3,300 new MCL cases are diagnosed annually in the United States. While many patients respond to initial treatment, relapse is common and prognosis after progression can be poor, particularly following prior BTK inhibitor therapy. The accelerated approval of sonrotoclax introduces a new targeted mechanism to the MCL treatment landscape and underscores the importance of expanding options as the disease evolves.